$40 Million

MDxHealth SA

Lead Left Bookrunner, February 2023

MDxHealth SA

MDxHealth SA (NASDAQ: MDXH) / (ENXTBR: MDXH) (“MDxHealth” or the “Company”) is a commercial-stage precision diagnostics company committed to providing non-invasive, clinically actionable and cost-effective urologic solutions to improve patient care. MDxHealth’s novel prostate cancer genomic testing solutions combine advanced clinical modeling with genomic data to provide each patient with a personalized cancer risk profile, which provides more accurate and actionable information than standard risk factors (e.g., PSA, DRE, age) used by clinicians.  The Company’s Select mdx and Confirm mdx solutions address men at risk for developing prostate cancer, providing physicians with a clear clinical pathway to accurately identify clinically significant prostate cancer while minimizing the use of invasive procedures that are prone to complications. MDxHealth’s Genomic Prostate Score (GPS) solution addresses men newly diagnosed with early-stage prostate cancer, providing physicians with a clear clinical pathway to make the most informed treatment decision for their individual disease, including active surveillance.  MDxHealth’s collective decades of experience in precision diagnostics and its portfolio of novel biomarkers for diagnostic, prognostic and predictive molecular assays supports the Company’s active pipeline of new testing solutions for prostate and other urologic diseases.

More Like This

Mar 2024

Autovista has been acquired by J.D. Power, a portfolio company of Thoma Bravo

Exclusive Financial Advisor

View Details >
Feb 2024
$430 Million

Common Stock PIPE (and Served as Financial Advisor in the Closing of Business Combination with Flame Acquisition Corp. – NYSE:FLME)

Lead Placement Agent

View Details >
Jan 2024
$250 Million

Follow-on Offering

Bookrunner

View Details >